Peritoneal dialysis – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:33:08 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Peritoneal dialysis – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Cefepime for Patients with Chronic Kidney Disease on Peritoneal Dialysis Without Peritonitis https://clinicaltrials.eu/trial/study-on-cefepime-for-patients-with-chronic-kidney-disease-on-peritoneal-dialysis-without-peritonitis/ Wed, 29 Apr 2026 14:30:10 +0000 https://clinicaltrials.eu/trial/study-on-cefepime-for-patients-with-chronic-kidney-disease-on-peritoneal-dialysis-without-peritonitis/ This clinical trial is focused on studying the effects of the antibiotic cefepime in patients with Chronic Kidney Disease (CKD) stage 5 who are undergoing a type of dialysis called Peritoneal Dialysis. The study aims to understand how cefepime behaves in the body when it is administered directly into the abdominal cavity through a process known as cycler-therapy. This method is used in patients who do not have an infection called peritonitis, which is an inflammation of the lining of the abdominal cavity.

The purpose of the study is to determine if there is enough concentration of cefepime in the blood and the dialysis fluid to be effective. The study will also look at how the drug moves through the body and how it is processed, which is known as its pharmacokinetics and pharmacodynamics. Participants will receive cefepime through an injection or infusion, and the study will monitor how the drug is absorbed, distributed, and eliminated over a period of time.

Throughout the study, participants will be observed to see how their bodies respond to the treatment. The study will measure various factors, such as the highest concentration of the drug in the blood and how long it takes to reach this level. This information will help researchers understand the effectiveness of cefepime when used in this specific way for patients with CKD stage 5 on Peritoneal Dialysis.

]]> Study on the Safety and Effectiveness of Apixaban and Warfarin for Patients with End-Stage Renal Disease on Peritoneal Dialysis and Atrial Fibrillation https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-apixaban-and-warfarin-for-patients-with-end-stage-renal-disease-on-peritoneal-dialysis-and-atrial-fibrillation/ Wed, 29 Apr 2026 14:29:04 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-apixaban-and-warfarin-for-patients-with-end-stage-renal-disease-on-peritoneal-dialysis-and-atrial-fibrillation/ This clinical trial is focused on studying the safety and effectiveness of two medications, apixaban and warfarin, in patients with a specific heart condition known as non-valvular atrial fibrillation who are also undergoing peritoneal dialysis due to end-stage renal disease. Non-valvular atrial fibrillation is a type of irregular heartbeat that is not caused by a heart valve issue, and peritoneal dialysis is a treatment for kidney failure that uses the lining of the abdomen to filter blood inside the body.

The purpose of the study is to compare the safety of apixaban and warfarin by looking at the occurrence of bleeding events. Participants in the study will be randomly assigned to receive either apixaban or warfarin. The study will last for about a year, during which time participants will take the medication in tablet form by mouth. Throughout the study, researchers will monitor for any major or minor bleeding, as well as other health events like stroke, heart attack, or death from any cause.

Participants will have regular check-ups to assess their health and the effects of the medication. The study aims to provide valuable information on which medication might be safer and more effective for patients with non-valvular atrial fibrillation who are on peritoneal dialysis. This information could help doctors make better treatment decisions for these patients in the future.

]]> Study on the Safety and Effectiveness of Warfarin for Patients with Atrial Fibrillation Undergoing Dialysis https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-warfarin-for-patients-with-atrial-fibrillation-undergoing-dialysis/ Wed, 29 Apr 2026 14:24:58 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-warfarin-for-patients-with-atrial-fibrillation-undergoing-dialysis/ This clinical trial is focused on studying the safety and effectiveness of a medication called Warfarin in patients who have both atrial fibrillation and end-stage renal disease. Atrial fibrillation is a condition where the heart beats irregularly, and end-stage renal disease is the last stage of chronic kidney disease where the kidneys can no longer function on their own. Patients with these conditions often require dialysis, a treatment that helps to filter and clean the blood using a machine.

The purpose of this study is to understand how well Warfarin, a medication that helps prevent blood clots, works in patients who are on dialysis and have atrial fibrillation. The study will compare patients taking Warfarin with those who are not receiving any treatment to see if there are differences in the occurrence of events like strokes or transient ischemic attacks, which are often referred to as mini-strokes. The study will also look at the risk of major bleeding, which can occur in different parts of the body, such as the brain or stomach.

Participants in the study will be randomly assigned to either receive Warfarin or no treatment. The study will be conducted over a period of time, and researchers will monitor the health of the participants to gather information on the safety and effectiveness of the medication. This information will help doctors understand the best ways to treat patients with atrial fibrillation who are also undergoing dialysis.

]]>